Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PBFT-02 by Passage Bio for Frontotemporal Dementia (FTD): Likelihood of Approval
PBFT-02 is under clinical development by Passage Bio and currently in Phase II for Frontotemporal Dementia (FTD). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Passage Bio's PBGM-01?
PBGM-01 is a gene therapy commercialized by Passage Bio, with a leading Phase II program in GM1 Gangliosidosis (Beta Galactosidase...
Risk adjusted net present value: What is the current valuation of Passage Bio's PBFT-02?
PBFT-02 is a gene therapy commercialized by Passage Bio, with a leading Phase II program in Frontotemporal Dementia (FTD). According...